Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment

Area of Science:

• Cardiovascular Science
• Immunology
• Biomedical Engineering

Background:

• Myocardial infarction (MI) is a leading cause of death globally, characterized by inflammatory responses that can lead to adverse cardiac remodeling.
• Uncontrolled inflammation post-MI contributes to cardiac dysfunction, scarring, and poor patient outcomes.
• Effective inflammation-regulating treatments are crucial for managing MI and improving patient prognosis.

Purpose of the Study:

• To review immune cells and fibroblasts involved in MI pathogenesis.
• To summarize novel drug delivery systems for MI treatment, focusing on inflammatory cell targeting.
• To highlight recent trends and strategies in developing targeted therapies for MI.

Main Methods:

• Literature review of immune responses in myocardial infarction.
• Summary of emerging drug delivery systems including hydrogels, cardiac patches, nanoparticles, and extracellular vesicles.
• Analysis of inflammatory cell-targeting strategies for MI treatment.

Main Results:

• Identified key immune cells and fibroblasts contributing to MI progression.
• Detailed various advanced drug delivery platforms designed for targeted therapy.
• Highlighted the potential of strategies that specifically target inflammatory cells for enhanced MI treatment.

Conclusions:

• Targeted drug delivery systems offer a promising therapeutic avenue for myocardial infarction by modulating the inflammatory response.
• Novel delivery systems like nanoparticles and EVs show potential for precise delivery to inflammatory sites.
• Further development of these targeted strategies is essential for effective MI management and improved cardiovascular health.